Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. - Test2 - elhamkhani - TriplyDB

Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.

Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.

http://www.wikidata.org/entity/Q33928258

about

Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients Axillary surgery in women with sentinel node-positive operable breast cancer: a systematic review with meta-analyses New trends in breast cancer surgery: a therapeutic approach increasingly efficacy and respectful of the patient Landmark trials affecting the surgical management of invasive breast cancer Clinical and technological transition in breast cancer Use of indocyanine green for detecting the sentinel lymph node in breast cancer patients: from preclinical evaluation to clinical validation Current status of optical imaging for evaluating lymph nodes and lymphatic system Axillary treatment for operable primary breast cancer.Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer.Optimal approach in early breast cancer: Radiation therapy Sentinel lymph node biopsy in breast cancer: predictors of axillary and non-sentinel lymph node involvement.Advances in managing breast cancer: a clinical update Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer.Use of Fluorescence Imaging in Combination with Patent Blue Dye versus Patent Blue Dye Alone in Sentinel Lymph Node Biopsy in Breast Cancer A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy New concepts in axillary management of breast cancer Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).Which patients need an axillary clearance after sentinel node biopsy?CAGS and ACS Evidence Based Reviews in Surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer-A multicenter randomized phase III clinical trial (SENORITA trial) protocol.Feasibility and diagnostic performance of dual-tracer-guided sentinel lymph node biopsy in cT1-2N0M0 gastric cancer: a systematic review and meta-analysis of diagnostic studies Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literature Role of Combined Sentinel Lymph Node Biopsy and Axillary Node Sampling in Clinically Node-Negative Breast Cancer Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients.The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies.Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer Is blue dye still required during sentinel lymph node biopsy for breast cancer?Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center.Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial.Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?Positive lymph nodes do not metastasize.The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care.The changing role of axillary lymph node dissection for breast cancer.Management of the axilla in early breast cancer patients in the genomic era.Blue dye is sufficient for sentinel lymph node biopsy in breast cancer.Management of operable primary breast cancer in older women.Histological examination of sentinel lymph nodes: significance of macrometastasis, micrometastasis, and isolated tumor cells.

P2860

Q24630857-93FF25B9-F484-4D74-A247-612135DA07FA Q26768675-DAE03E81-1B46-435E-AA8F-963D44176E35 Q26771845-BB5D95F8-12C7-409E-B4D9-E16B90244236 Q26830129-0FD25F78-00D1-4228-B967-A55A83B44923 Q26863300-80B2CD23-B7B2-4083-ADD4-A2F97F48652F Q27336227-499C24A2-AAEB-4249-8006-718CEAD7FC15 Q28084712-3C26F1D1-FEE8-4770-A1D0-BB227CC684EA Q30239832-09171995-B141-412F-B94B-7E55FF9196B4 Q30502656-CF99FED1-410D-44CD-9B44-983B33162D7B Q33699050-DBFFC75B-A7D3-48FD-9315-B868E37BAAEB Q33974092-0AA7A389-EA89-4920-8A64-A37898F4420E Q34019904-886365ED-8950-422D-9494-F8626EA3576C Q34278820-235E9F6C-12CA-4ECE-8901-785D930BC7A8 Q34340615-3596AA8C-FFE5-4B22-A21C-C5C12604E258 Q34506774-2D36E8B7-AAF4-4CF7-917F-61792540299A Q34657725-E87DF462-9F59-44DE-9F1B-E3448940F1D0 Q34919537-D38A50FE-0436-48E9-969E-36550F4EF537 Q35073164-259AF8AD-C142-4218-B309-5E9C852B172F Q35684387-670D669B-0B38-4A0B-8C18-C51E4603E9BC Q35722133-47F47681-2985-420C-884E-935A0D6BC064 Q36035480-163FD26D-76C3-42CF-BCCD-0AF898A7EDB3 Q36373547-F31C44C1-75E1-4914-823F-B825B08041C8 Q36420776-1ECF07D9-E778-49B5-B137-6595EA2654F9 Q36552723-A531E0E4-E556-4A96-BC99-5B58CA7FAE88 Q36887341-89453211-F1D2-4416-A9B9-AE9FB3244B76 Q36922539-505F7883-A0BB-4971-9568-3091C682262F Q36926908-F92C6946-11AE-4E7E-9030-1EBCE8A92651 Q37301533-2CBB190F-CA57-42BC-832D-15C36C89076E Q37452326-A5234F55-1320-44BD-873B-590999E5B058 Q37507146-D7B8FB74-2440-443A-8E5C-D6E67A8E97C8 Q37604182-F389CAE3-A8FA-4187-9037-41997574B9AA Q37709879-49659A68-B31A-4C36-ADA6-F50FD801BCB0 Q37869394-20466777-1BF2-439D-ADE7-0640B6BE5C0A Q37971305-54FC7C6B-3882-41FC-8CA4-CBB5951E5899 Q38021382-895BC212-08C0-4055-8BBD-BD9191A4D950 Q38051233-BF64227A-B7BC-4FB6-BE01-7FAA2C675AD9 Q38061094-DF9A559B-22B7-4DEE-83A4-07D865BC2357 Q38184924-2F83D327-D53A-4530-8777-6441D71F5871 Q38254650-8262E6F1-E8CE-4E20-B663-5B2A54677704 Q38348404-7028E6E3-CF23-4FF5-A488-4D376C4C532B

P2860

Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.

http://www.wikidata.org/entity/Q33928258

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sentinel node identification r ...... ORTC 10981-22023 AMAROS trial.

@ast

Sentinel node identification r ...... ORTC 10981-22023 AMAROS trial.

@en

type

label

Sentinel node identification r ...... ORTC 10981-22023 AMAROS trial.

@ast

Sentinel node identification r ...... ORTC 10981-22023 AMAROS trial.

@en

prefLabel

Sentinel node identification r ...... ORTC 10981-22023 AMAROS trial.

@ast

Sentinel node identification r ...... ORTC 10981-22023 AMAROS trial.

@en

P1433

Q33928258-B5C4E500-8292-43B0-BAD5-78EEE7C3D753

P1476

Q33928258-7C2F8AFF-7C2A-4C5A-84A3-A892FBACAB09

P2093

Q33928258-113E2324-C6CC-4DA6-956B-6E8E3089D23C

Q33928258-1AD10212-2F22-4E21-B3B3-93223336CD6E

Q33928258-530FC506-F393-45BB-A4C2-C8EB896F2E80

Q33928258-5A815F73-32F1-436E-9F7C-18F0E57EB0DE

Q33928258-621BA178-8EEA-4197-802A-D03C17F9F9B2

Q33928258-6ED83164-0A5F-44F9-9AD7-D45F6E957AEC

Q33928258-8620CAA0-210F-4239-90A2-0AA93FC0B545

Q33928258-A87AA1AB-3703-4FB4-8E16-293F67A130D6

Q33928258-BE21F2BD-F048-4872-ACDE-4DF85B336202

Q33928258-C02D596F-4517-48F5-B3D5-4A307C40DA95

P2860

Q33928258-285AD3FA-B543-41A3-AA4C-F348224D1820

Q33928258-2AE68392-D31F-4BE2-85DD-C6DE5EC21800

Q33928258-2E86ED8B-CE2D-470F-AAF9-97E0922DD88C

Q33928258-50D6E901-7599-4F2D-9811-636AD3C3A388

Q33928258-53F4E031-5BA4-45B3-9BEC-02339D64311C

Q33928258-58ED64DA-BE5A-4DC1-B3B8-99AC8158DA3C

Q33928258-5B39A189-F77B-4CF1-835A-0AE9A8AD0FD6

Q33928258-605DDEE5-096C-4F05-A239-0C5623B75CEA

Q33928258-7196737B-0B1A-4932-8249-6D73A7766510

Q33928258-742A9AC7-E45A-4C7A-8C2C-6CFC876F2A3A

P2888

Q33928258-B7FB9368-BEE2-4CED-B683-8C75A4082F68

P304

Q33928258-9841A469-71EC-4AA7-8881-1E4985ECAA40

P31

Q33928258-A229792C-D279-4387-B956-56E98D4F4CF5

P356

Q33928258-7E797400-1087-46F9-9503-4BE30AC31062

P433

Q33928258-A5791BF2-6B90-4C14-A173-09412F85D157

P478

Q33928258-F68834DF-AECB-4AC2-85E5-C17C9C0DA044

P577

Q33928258-762A502F-5A06-4854-8D69-9D0407F27EB1

P5875

Q33928258-5FC457B5-9CFD-4578-8208-BA7C248DF5AD

P6179

Q33928258-793AE96E-D91A-4927-8D24-BE79440C802A

P698

Q33928258-721CEBD1-24B0-4750-ABF8-966BB9669B40

P932

Q33928258-517C5EDB-DF3B-40D4-832F-25859D650F96

P356

S10434-010-0945-Z

P1433

Annals of Surgical Oncology

P1476

Sentinel node identification r ...... ORTC 10981-22023 AMAROS trial.

@en

P2093

Coen Hurkmans

http://www.w3.org/2001/XMLSchema#string

Cornelis J H van de Velde

http://www.w3.org/2001/XMLSchema#string

Emiel J T Rutgers

http://www.w3.org/2001/XMLSchema#string

Geertjan van Tienhoven

http://www.w3.org/2001/XMLSchema#string

Helen A Westenberg

http://www.w3.org/2001/XMLSchema#string

Huub van der Mijle

http://www.w3.org/2001/XMLSchema#string

Jan Bogaerts

http://www.w3.org/2001/XMLSchema#string

Jean H G Klinkenbijl

http://www.w3.org/2001/XMLSchema#string

Luigi Cataliotti

http://www.w3.org/2001/XMLSchema#string

Marieke E Straver

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group

Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.

Lymphatic mapping and sentinel lymph node biopsy in breast cancer.

Factors predicting failure to identify a sentinel lymph node in breast cancer.

Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection.

Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node

Axillary recurrence after sentinel node biopsy.

Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature.

Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer.

Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes.

P2888

s10434-010-0945-z

P304

1854-1861

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-010-0945-Z

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42346514

http://www.w3.org/2001/XMLSchema#string

P6179

1029340722

http://www.w3.org/2001/XMLSchema#string

P698

20300966

http://www.w3.org/2001/XMLSchema#string

P932

2889289

http://www.w3.org/2001/XMLSchema#string